Clotrimazole

# Clotrimazole ## Overview - **Classification**: Azole Antifungal - **Mechanism**: Inhibits the biosynthesis of ergosterol, a critical component of fungal cell membranes. This leads to structural and functional impairment of the fungal cell membrane, resulting in fungal cell death. ## Primary Indications 1. **Vaginal Candidiasis (Vulvovaginal Candidiasis - VVC)** - Treatment of yeast infections. 2. **Oropharyngeal Candidiasis (Oral Thrush)** - Treatment of candidal infections of the mouth and throat. 3. **Dermatological Fungal Infections** - Treatment of tinea infections (e.g., ringworm, athlete's foot, jock itch) and cutaneous candidiasis. ## Adult Dosing ### Standard Dosing **Vaginal Candidiasis** - **Cream 1%**: **1 applicatorful (5 g)** - **Frequency**: Once daily - **Route**: Intravaginal - **Duration**: **7-14 days** - **Cream 2%**: **1 applicatorful (5 g)** - **Frequency**: Once daily - **Route**: Intravaginal - **Duration**: **3-7 days** - **Vaginal Tablet 100 mg**: **1 tablet** - **Frequency**: Once daily - **Route**: Intravaginal - **Duration**: **7 days** - **Vaginal Tablet 200 mg**: **1 tablet** - **Frequency**: Once daily - **Route**: Intravaginal - **Duration**: **3 days** - **Vaginal Tablet 500 mg**: **1 tablet** - **Frequency**: Single dose - **Route**: Intravaginal - **Duration**: **1 day** **Oropharyngeal Candidiasis** - **Troche (Oral Lozenge) 10 mg**: **1 troche (10 mg)** - **Frequency**: 5 times daily (every 3 hours while awake) - **Route**: Oral (dissolve slowly in mouth) - **Duration**: **14 consecutive days** - **Maximum Dose**: **50 mg/day** **Dermatological Fungal Infections** - **Cream 1%, Solution 1%**: Apply **thin layer** to affected areas - **Frequency**: Twice daily - **Route**: Topical - **Duration**: **2-4 weeks** (depends on infection type, e.g., tinea pedis up to 4 weeks). ### Dose Adjustments - **Renal Impairment**: No specific dose adjustments needed for topical or oral troche formulations due to minimal systemic absorption. - **Hepatic Impairment**: No specific dose adjustments needed for topical or oral troche formulations. - **Elderly Patients**: No specific dose adjustments needed. Use with caution for oral troches if patient has difficulty dissolving lozenge safely. ## Pediatric Dosing ### Neonates (0-28 days) - **Topical (Dermatological)**: Apply **1% cream** to affected area. - **Frequency**: Twice daily. - **Maximum**: Use sparingly. - **Special Notes**: Generally not recommended for oral thrush; nystatin suspension is preferred due to choking risk with troches. ### Infants (1-12 months) - **Topical (Dermatological)**: Apply **1% cream** to affected area. - **Frequency**: Twice daily. - **Special Notes**: Not recommended for oral thrush; nystatin suspension is preferred. ### Children (1-12 years) - **Oropharyngeal Candidiasis (≥ 3 years, able to suckle)**: **1 troche (10 mg)** dissolved slowly in mouth. - **Frequency**: 5 times daily (every 3 hours while awake). - **Maximum**: **50 mg/day**. - **Special Notes**: Ensure child can safely dissolve troche without choking. - **Topical (Dermatological)**: Apply **1% cream/solution** to affected areas. - **Frequency**: Twice daily. - **Maximum**: Adult duration (e.g., **2-4 weeks**). ### Adolescents (13-18 years) - **Dose**: As per adult dosing for all indications. - **Maximum**: Adult maximum doses apply. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to clotrimazole or any component of the formulation. - **Absolute**: Hypersensitivity to other azole antifungals (cross-reactivity possible). ### Common Adverse Effects - **Topical/Vaginal**: Burning, stinging, erythema, itching, irritation, rash. - **Oral Troche (1-10%)**: Abnormal liver function tests (monitor if prolonged use), nausea, vomiting, unpleasant taste, pruritus, GI upset. ### Key Drug Interactions - **Tacrolimus, Sirolimus (with oral troche)**: Oral clotrimazole is a moderate CYP3A4 inhibitor. May increase concentrations of these immunosuppressants. - **Clinical Significance**: Risk of nephrotoxicity and other adverse effects. - **Monitoring**: Monitor tacrolimus/sirolimus drug levels closely; dose reduction may be necessary. ## Monitoring & Follow-up - **Before Treatment**: N/A for routine topical/oral troche use. - **During Treatment**: Monitor for clinical improvement (reduction in symptoms/signs of infection). For oral troche, consider LFTs for prolonged use or high-risk patients. - **Clinical Signs**: Watch for worsening irritation, lack of improvement after expected duration, or development of new symptoms. ## Clinical Pearls - 💡 **Topical application**: Ensure affected area is clean and dry before applying cream/solution. - 💡 **Vaginal cream/tablets**: Complete the full course of treatment, even if symptoms improve, to prevent recurrence. Avoid sexual intercourse during treatment. - 💡 **Oral troches**: Allow to dissolve slowly and completely in the mouth; do not chew or swallow whole. Avoid eating or drinking immediately after use. - 💡 **Contact Dermatitis**: Discontinue use if irritation or sensitization develops. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.